Reporters/editors/producers note: The following feature was produced by the American Psychological Association. You may reprint it in its entirety or in part. We only request that you credit APA as the source. A photograph of Dr. Smith is available upon request.
Alzheimer’s disease is a chronic brain disease that gradually erodes an individual’s memory, intellectual abilities and personality. As of 2012, an estimated 5.2 million Americans — one in eight people age 65 or older — have Alzheimer’s, according to the Alzheimer’s Association. And this number is expected to increase rapidly as America’s baby boomers reach retirement age. Psychologists play an important role in the prevention, diagnosis and treatment of this disease, which is the sixth leading cause of death in the United States.
Glenn E. Smith, PhD, is a consultant in the Division of Neurocognitive Disorders, Department of Psychiatry & Psychology at the Mayo Clinic in Rochester, Minn. He is associate director of Clinical and Translational Sciences Education Programs at the Mayo Foundation for Medical Education and Research and clinical director of Alzheimer’s disease resources on MayoClinic.com. Smith received his PhD in clinical psychology from the University of Nebraska. He completed an internship in neuropsychology-geropsychology at UCLA’s Neuropsychiatric Institute and a post-doctoral fellowship in clinical neuropsychology and rehabilitation at the Mayo Medical School. He is past president of APA’s Div. 40 (Clinical Neuropsychology) and the American Board of Clinical Neuropsychology.
APA recently asked him the following questions:
APA: News about Alzheimer’s frequently focuses on the use of medications to treat the disease. Are there behavioral treatments that can help without medication?
Dr. Smith: Outcomes of clinical trials with medications for treating Alzheimer’s have been disappointing. Historically, these clinical trials involved patients with dementia because the presence of dementia was required for the diagnosis of Alzheimer’s disease. There is a growing concern that by the time dementia is present, the brain may be so ravaged that treatment at that point cannot be effective. Recently, substantial progress has been made in the ability to detect Alzheimer’s before dementia is present. For example, we can now reliably diagnose mild cognitive impairment. This ability has given rise to secondary prevention strategies that seek to prevent or delay progression to full dementia. A variety of behavioral treatments show promise as secondary prevention strategies. At the Mayo Clinic, we have launched an intensive multicomponent intervention that combines daily physical activity, cognitive exercise, a memory compensation strategy, wellness education and support groups. We’ve observed that this intervention produces short-term improvement and longer-term stabilization of a patient’s ability to function.
APA: What is early-onset Alzheimer’s and do the symptoms differ between early-onset and when it occurs at a later age?
Dr. Smith: In normal aging, processing speed declines and word finding may worsen, but memory is relatively spared. By contrast, the hallmark first sign of Alzheimer’s disease is forgetting. Indications of the illness first appear in brain structures that are critical for new learning and delayed recall of information. The disease soon spreads to regions supporting more complex understanding of language and executive function, which covers basic mental tasks such as planning, strategizing, organizing and setting goals. Simple attention (including processing speed), visual-spatial reasoning and other aspects of speech and language are generally spared early on. In distinction, with another form of dementia known as Lewy Body disease, organizing visual information and understanding how it can change if movement occurs and other aspects of attention are impaired early. Attention is also compromised early in vascular-based cognitive impairment. By recognizing these cognitive differences, neuropsychological assessment can contribute to early diagnosis among the various types of dementia.
Early-onset dementia is a label applied when the diagnosis is before age 65. Clinically, Alzheimer’s disease presents pretty much the same at age 63 as at age 83. But Alzheimer’s disease is highly associated with advancing age. For other causes of dementia, like fronto-temporal dementia and Lewy Body disease, peak incidence is at a younger age. So, early-onset dementia has a greater probability of not being caused by Alzheimer’s. Thus, differences between early- and late-onset dementias are based more in the different age-specific incidences of the various causes for dementia.
APA: If someone has parents and grandparents diagnosed with Alzheimer’s, is it inevitable that person will someday also suffer from the disease? In other words, what is the role of genetics in the development of Alzheimer’s?
Dr. Smith: There are three major genes known to cause dementia and these genes follow what is known as the Mendelian inheritance pattern, in which the genetic trait displayed results from one parent’s gene dominating over a gene inherited from the other parent. But these three genes are present in less than 5 percent of all dementia cases. There are also genes that increase susceptibility to develop Alzheimer’s. The most notable of the susceptibility genes is the Apolipoprotein E (ApoE) gene. Carrying one copy of the ε4 form of the ApoE gene increases your risk up to four times. But you can carry the risky form of this gene and still not develop dementia, and many people develop the disease without carrying the ε4 gene. Finally, a family history of Alzheimer’s irrespective of ε4 status does increase your risk of developing the disease. Yet even with a family history, the chances are still greater that you will die without developing Alzheimer’s disease than with the disease, provided you do not carry a causative gene.
APA: What are the most important steps a person can take to prevent onset of the disease?
Dr. Smith: Physical and mental inactivity, smoking, obesity, diabetes, hypertension and depression (each modifiable by behavioral intervention) have been shown to be risk factors for the development of Alzheimer’s disease. Barnes and Yaffee, (Lancet Neurology, 2011) suggest that 25 percent improvement in these conditions among the general population would prevent as many as 16.5 percent of Alzheimer’s disease cases in the United States.
APA: How will the Obama administration’s National Alzheimer’s Plan incorporate behavioral health as part of a strategy to bring about a cure for Alzheimer’s disease?
Dr. Smith: The National Alzheimer’s Plan, released in May, involves five major strategies:
- prevent and effectively treat Alzheimer’s disease by 2025
- optimize care, quality and efficiency
- expand support for people with Alzheimer’s disease and their families
- enhance public awareness and engagement
- track progress and drive improvement
Each strategy is associated with several actions. With smoking, eating unhealthy foods and not getting enough physical or mental exercise among preventable risk factors for development of Alzheimer’s, behavior change strategies will play a critical role in the development and implementation of prevention programs. These treatment programs will include daily physical activity, cognitive and memory exercises and support groups.
To ensure timely and accurate diagnoses, psychologists, especially those who specialize in aging or cognition science, are particularly well positioned to recognize, formally assess and explain the implications of cognitive changes associated with the diagnosis of mild cognitive impairment. Additionally, as more people find themselves in the role of caregiver for a family member with Alzheimer’s, psychologists are responding by developing state-of-the-art interventions to enhance caregiver resilience.
Dr. Smith can be contacted through Nick Hanson, Mayo Clinic Public Affairs, at (507) 266-4945 (office), (651) 235-2265 (cell), or by email.
The American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States and is the world’s largest association of psychologists. APA’s membership includes more than 137,000 researchers, educators, clinicians, consultants and students. Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance psychology as a science, as a profession and as a means of promoting health, education and human welfare.